Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)‘s stock had its “outperform” rating reissued by analysts at FBR & Co in a note issued to investors on Wednesday. They presently have a $9.00 target price on the stock. FBR & Co’s price objective points to a potential upside of 101.34% from the stock’s current price.
AUPH has been the topic of a number of other reports. Canaccord Genuity restated a “buy” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Saturday. HC Wainwright lifted their price objective on shares of Aurinia Pharmaceuticals from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, August 17th. Finally, Leerink Swann reaffirmed an “outperform” rating on shares of Aurinia Pharmaceuticals in a research note on Tuesday, August 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $7.75.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down 1.34% during midday trading on Wednesday, reaching $4.41. 1,006,417 shares of the company were exchanged. The company’s market capitalization is $155.61 million. Aurinia Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $5.69. The stock’s 50-day moving average price is $2.59 and its 200-day moving average price is $2.80.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AUPH. Abingworth LLP increased its position in Aurinia Pharmaceuticals by 479.8% in the second quarter. Abingworth LLP now owns 512,036 shares of the company’s stock valued at $1,388,000 after buying an additional 423,729 shares during the period. Lombard Odier Asset Management USA Corp increased its position in Aurinia Pharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the company’s stock valued at $283,000 after buying an additional 2,813 shares during the period. Finally, Creative Planning purchased a new position in Aurinia Pharmaceuticals during the third quarter valued at $181,000. 20.04% of the stock is currently owned by institutional investors and hedge funds.
About Aurinia Pharmaceuticals